About Antev
Antev is a company based in London (United Kingdom) founded in 2013 by Oliver Bates was acquired by Medicus Pharma in April 2025. The company has 9 employees as of December 31, 2020. Antev operates in a competitive market with competitors including Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
- Headquarter London, United Kingdom
- Employees 9 as on 31 Dec, 2020
- Founders Oliver Bates
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Antev Limited
- Date of Incorporation 06 Nov, 2013
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
9
as on Dec 31, 2020
-
Acquired by
Medicus Pharma
(Apr 28, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Antev
Detailed funding history for Antev
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Antev
Antev has secured backing from 1 investor. Prominent investors backing the company include Medicus Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Clinical stage, multi-strategy holding company focused on investing in and accelerating novel therapies in the biotechnology and life sciences industry
|
Locked | Locked | Locked |
Investor details for Antev
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Antev
Investment portfolio details for Antev
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Antev
Detailed financials for Antev
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Antev Comparisons
Peer comparison for Antev
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Antev
Antev operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Lipid-based therapies for common bladder syndromes are developed.
|
|
| Locked | Locked | Locked |
Clinical stage biopharma company developing drugs for urology and central nervous system disorders
|
|
| Locked | Locked | Locked |
Develop drugs for genitourinary (GU) disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat renal diseases
|
|
| Locked | Locked | Locked |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| Locked | Locked | Locked |
Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments.
|
Detailed competitors of Antev
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Antev
Complete news archive for Antev
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antev
Antev was founded in 2013.
Antev is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
As of Dec 31, 2020, the latest employee count at Antev is 9.
Antev is a biotechnology company with a focus on urology. The companys flagship products are based on a technology called as Teverelix, a patented and proprietary long-acting GnRH (gonadotrophin releasing hormone) antagonist and targeted for the indications of benign prostatic hyperplasia and acute urinary retention. Teverelix has completed phase II is ready to undergo phase III trials for benign prostatic hyperplasia, prostate cancer phase I for endometriosis. The company is also trying to useTeverelix for veterinary applications.
Antev's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
Antev has 1 investor. Key investors include Medicus Pharma.